Findings: Don’t blame patients for all inhaler-use errors; singing may help improve breathing, QOL; Rx adherence does improve over time; plus 3 more outcomes of interest.
Budesonide-Based Triple Therapy Most Cost-Effective vs Dual Therapy for COPD
A new analysis found triple therapy for COPD, particularly B/G/F, more cost-effective vs dual therapy in terms of exacerbations and quality-adjusted life years.
Respiratory Tripledemic 2022-23: An Expert Recap
William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.
Anxiety Raises Risk for Acute Exacerbations in Older Adults with COPD: Daily Dose
Your daily dose of the clinical news you may have missed.
NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half
In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.
Breathlessness Related to Medical Conditions in Middle-Aged Adults: Daily Dose
Decrease in BMI Linked to Increased Risk for Severe Exacerbations, All-Cause Mortality in COPD
Among persons with COPD whose BMI decreased over a 4-year follow-up, mortality risk rose 70% compared with those whose BMI remained the same, researchers reported.